SCYNEXIS (SCYX) Received its Third Buy in a Row

After Maxim Group and H.C. Wainwright gave SCYNEXIS (NASDAQ: SCYX) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on SCYNEXIS today and set a price target of $6. The company’s shares closed on Friday at $1.

According to TipRanks.com, Higgins has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.4% and a 26.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.

SCYNEXIS has an analyst consensus of Strong Buy, with a price target consensus of $4.42, a 342.0% upside from current levels. In a report issued on July 31, Aegis Capital also initiated coverage with a Buy rating on the stock with a $3 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.90 and a one-year low of $0.35. Currently, SCYNEXIS has an average volume of 330K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.